DSM-Firmenich AG (DSFIY) Q2 2026 Earnings Call Transcript
DSM-Firmenich is a high-quality specialty chemicals company focused on inelastic, high-margin nutrition, health, and beauty ingredients. Following the divestment of its volatile animal nutrition segment, DSM-Firmenich now boasts a robust A-rated balance sheet, strong FCF, and a well-covered 3%+ dividend. Despite historical premium valuations, I assign a forward P/E of 17-18x, reflecting justified but moderate premiumization versus peers, with a price target of €67.8/share.
DSM-Firmenich AG (DSFIY) Q1 2026 Sales/Trading Call Transcript
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| PER Paul E. Rasmussen SIT INVESTMENT ASSOCIATES Inc. | 2.24M | $13.42M | $13.16M | -$260,725.93 | -1.94% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 2,700 | $16,227 | $15,849 | -$378 | -2.33% |
Daniel L. Lippincott Karpus Management Inc. | 936,572 | $5.28M | $5.49M | $205,519.65 | 3.89% |
Bulldog Investors Bulldog Investors LLP | 3.07M | $18.09M | $17.96M | -$126,790.27 | -0.7% |
| PF Phillip Fitzsimmons Hennion & Walsh Asset Management Inc. | 1.48M | $8.89M | $8.58M | -$314,434.56 | -3.54% |